Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Clinical Summary

Latent Tuberculosis Infection: Screening

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Population Asymptomatic adults at increased risk for infection
Recommendation Screen for latent tuberculosis infection (LTBI).
Grade: B
Risk Assessment Populations at increased risk for LTBI include persons who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (eg, homeless shelters and correctional facilities). Local demographic patterns may vary across the United States; clinicians can consult their local or state health departments for more information about populations at risk in their community.
Screening Tests Screening tests include the Mantoux tuberculin skin test and interferon-gamma release assays; both are moderately sensitive and highly specific for the detection of LTBI.
Treatment and Interventions The CDC provides recommendations for the treatment of LTBI at
Balance of Benefits and Harms The USPSTF concludes with moderate certainty that the net benefit of screening for LTBI in persons who are at increased risk for tuberculosis is moderate.

For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to

Abbreviations: CDC=Centers for Disease Control and Prevention; USPSTF=US Preventive Services Task Force.

Current as of: September 2016

Internet Citation: Clinical Summary: Latent Tuberculosis Infection: Screening. U.S. Preventive Services Task Force. January 2017.

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857